Compare Neurocrine Biosciences Inc (NBIX) vs Opendoor Technologies Inc (OPEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Opendoor Technologies Inc — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while Opendoor Technologies Inc trades at $2.97 (market cap $2.89B). The key difference: Neurocrine Biosciences Inc is far larger — about 5.5× Opendoor Technologies Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Opendoor Technologies Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | OPEN | |
|---|---|---|
Market Cap | $15.77B | $2.89B |
Sector | Health | Real Estate |
52-Week High | $185.50 | $10.52 |
52-Week Low | $123.10 | $3.00 |
Enterprise Value | $15.78B | $3.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Opendoor Technologies (OPEN) trades at $3.07, down 2.54% on the day, near its 52-week low. The stock shows a bearish technical trend with mixed oscillators. Fundamentally, revenue declined to $4.37 billion in 2025 with a net loss of $1.30 billion, though cash flow improved. Recent news highlights expansion into mortgage lending and a share buyback program.
The outlook remains challenging due to persistent losses and housing market headwinds, but cost-cutting and volume growth offer potential upside. Risks include high debt, competitive pressure, and interest rate sensitivity. Analysts are mostly neutral with a $3.58 price target, suggesting cautious optimism if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Opendoor Technologies Inc
Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →
